Get the Stockscreener App
1.19
1.65%
-0.02
After Hours:
1.19
AvroBio Inc stock is currently priced at $1.19, with a 24-hour trading volume of 348.45K.
It has seen a -1.65% decreased in the last 24 hours and a -7.03% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.21 pivot point. If it approaches the $1.18 support level, significant changes may occur.
Previous Close:
$1.21
Open:
$1.19
24h Volume:
348.45K
Market Cap:
$53.40M
Revenue:
-
Net Income/Loss:
$12.16M
P/E Ratio:
-8.50
EPS:
-0.14
Net Cash Flow:
$-63.20M
1W Performance:
-2.46%
1M Performance:
-7.03%
6M Performance:
-23.23%
1Y Performance:
+32.21%
1D Range:
$1.185
$1.21
52W Range:
$0.57
$1.70
AvroBio Inc Stock (AVRO) Company Profile
Name
AvroBio Inc
Sector
Industry
Phone
617 914 8420
Address
Building 300, Suite 201 One Kendall Square, Cambridge, MA
AvroBio Inc Stock (AVRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-22 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Buy |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Mar-31-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Apr-05-19 | Initiated | Janney | Buy |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-17-18 | Initiated | H.C. Wainwright | Buy |
| Jul-16-18 | Initiated | Morgan Stanley | Overweight |
| Jul-16-18 | Initiated | Wedbush | Outperform |
| Jul-16-18 | Initiated | Wells Fargo | Outperform |
View All
AvroBio Inc Stock (AVRO) Latest News
AvroBio Inc Stock (AVRO) Financials Data
AvroBio Inc (AVRO) Net Income 2024
AVRO net income (TTM) was $12.16 million for the quarter ending December 31, 2023, a +111.48% increase year-over-year.
AvroBio Inc (AVRO) Cash Flow 2024
AVRO recorded a free cash flow (TTM) of -$63.20 million for the quarter ending December 31, 2023, a +35.16% increase year-over-year.
AvroBio Inc (AVRO) Earnings per Share 2024
AVRO earnings per share (TTM) was $0.27 for the quarter ending December 31, 2023, a +111.20% growth year-over-year.
AvroBio Inc Stock (AVRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ostrowski Erik | Interim CEO, President and CFO |
Feb 01 '24 |
Option Exercise |
0.00 |
40,084 |
0 |
42,384 |
| Ridha Essra | Chief Medical Officer |
Feb 01 '24 |
Option Exercise |
0.00 |
32,834 |
0 |
32,834 |
| Avruch Steven | Chief Legal Officer |
Feb 01 '24 |
Option Exercise |
0.00 |
32,834 |
0 |
32,834 |
About AvroBio Inc
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
3.69%
0.93%
Cap:
|
Volume (24h):